Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: A study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell limes

被引:0
|
作者
Gazitt, Y [1 ]
Hu, WX [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Hematol, San Antonio, TX 78284 USA
关键词
bcl-2; transfection; myeloma; Fas; apoptosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eight myeloma cell lines with variable expression of bcl-2 were screened for the expression of the FAS antigen and for sensitivity to anti-FAS-induced apoptosis. Anti-FAS-induced apoptosis correlated positively (R=0.89) with the level of expression of the FAS antigen, and was independent of the expression of bcl-2. Forced expression of bcl-2 in 8226 and ARP-1 multiple myeloma (MM) cell lines expressing relatively low levels of bcl-2, resulted in 1-2 log increase in resistance to dexamethasone (DEX)-induced apoptosis. However, sensitivity to anti-FAS-induced apoptosis was unchanged in ARP-1 cells or was increased in 8226 cells, compared to the parental cell lines. The increased sensitivity to anti-FAS-induced apoptosis in 8226 cells was due to the increase in FAS expression in the bcl-2 transfected cells and was proportionate to the increase in FAS expression. Furthermore, we observed manyfold increase in the expression of Fas, CD40, CD45 and CD19 antigens, in 8226 cells, concomitant with a significant decrease in the expression of CD38 antigen. Thus, 8226 cells overexpressing bcl-2 appear to have an immature myeloma cell phenotype, have higher growth-rate and increased sensitivity to anti-FAS-induced apoptosis.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 50 条
  • [21] The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis
    Raisova, M
    Hossini, AM
    Eberle, J
    Riebeling, C
    Wieder, T
    Sturm, I
    Daniel, PT
    Orfanos, CE
    Geilen, CC
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 333 - 340
  • [22] Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-XL or Bcl-2
    Dirsch, VM
    Stuppner, H
    Vollmar, AM
    CANCER RESEARCH, 2001, 61 (15) : 5817 - 5823
  • [23] bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: A study with inducible bcl-2 transfection constructs
    Tian, EM
    Hu, WX
    Gazitt, Y
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (01) : 165 - 169
  • [24] Serum levels of Fas/Apo-1 and bcl-2 in children with HIV-1 infection
    Torre, D
    Zeroli, C
    Speranza, F
    Martegani, R
    Fiori, G
    Airoldi, M
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1998, 30 (06) : 565 - 568
  • [25] Hematopoietic stem cell survival requires both BCL-2 dependent and BCL-2 independent signals.
    Domen, J
    Weissman, IL
    BLOOD, 2000, 96 (11) : 70A - 70A
  • [26] Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)
    Demir, G
    Ozguroglu, M
    Sayhan, N
    Molinas-Mandel, N
    Demirelli, F
    Buyukunal, E
    Tuzuner, N
    Serdengecti, S
    Berkarda, B
    ANTICANCER RESEARCH, 1999, 19 (4C) : 3517 - 3520
  • [27] CD95 AND BCL-2 EXPRESSION AS APOPTOTIC MARKERS IN RHEUMATOID PATIENTS
    Ahmad, M. Sayed
    Elsawy, N.
    Imam, M.
    Gad, M.
    Alzawawy, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 198 - 198
  • [28] Inhibition of Fas-induced apoptosis by Bcl-2
    Kawahara, A
    Kobayashi, T
    Nagata, S
    ONCOGENE, 1998, 17 (20) : 2549 - 2554
  • [29] Inhibition of Fas-induced apoptosis by Bcl-2
    Atsuo Kawahara
    Toshiko Kobayashi
    Shigekazu Nagata
    Oncogene, 1998, 17 : 2549 - 2554
  • [30] Fas (CD95) and bcl-2 expression in active skin lesions of Behcet's disease
    Baris, YS
    Yildiz, L
    Sentürk, N
    Kandemir, B
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (05) : 569 - 572